Looking to sell Evozyne stock or options?
Evozyne operates a data-driven platform focused on evolution-based molecular engineering to design innovative proteins with enhanced capabilities. Their platform provides reliable models and insights into the physics of protein folding, function, and the evolutionary potential of synthetic drugs. This allows the healthcare industry to obtain tailored molecules that address specific challenges related to human health and bodily functions.
Nvidia, OrbiMed, nVentures, Fidelity Investments, Valor Equity Partners, Paragon Biosciences, NVentures (Santa Clara).
Evozyne is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Evozyne stock. Depending on Evozyne’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Evozyne stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Evozyne stock in two ways. First, Evozyne employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Evozyne stock. Note that all transactions in Evozyne shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Evozyne stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Evozyne stock. Typically, shares of private companies like Evozyne are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Sep 2023, Evozyne is reported to have closed an equity financing in which the investors valued the company at $288M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Evozyne shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Evozyne is not currently publicly traded, it does not have a ticker symbol.
Evozyne has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Evozyne is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Evozyne shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.